The use of ADRCs in the treatment of many different medical conditions (including cardiovascular disease, soft tissue defects, wound healing, and many more) is being evaluated in numerous clinical and preclinical studies around the world.
The use of ADRCs is a unique and promising approach and holds key advantages over stem and regenerative cells from other sources. While stem and progenitor cells usually make up less than 5% of all ADRCs, this is 2,500-fold more than the frequency of such cells in tissues such as bone marrow (0.002%). The abundance of ADRCs in adipose tissue and the ability to easily collect large amounts of adipose tissue via liposuction eliminates the need for tissue culturing.
ADRC´s hold key advantages over stem and regenerative cells from other sources.
This is the key statement. Every investor who isnt a molecular biologist has to wrestle through expert- and "lesser expert" explanations of financial analysts nowadays, who try to explain, over and over again, the differences in sources of cells and their ASSUMED potency and risks, when they discuss a company in the stem cell space. Most Cytori investors are now well acquainted with fancy words like pluripotency, multipotency etc. What key to know is, is that we at present still only see the top of the iceberg of the potential of ADRC´s. It has been 40 years that marrow cells have been studied and characterized. Caplan added the Mesenchymal stem cell to his and the scientific communities general knowledge about 20 years ago, but only since 5-10 years the scientific research has truly commenced in respect of ADRC´s. We are going from, yes they look like BMRC´s to -yes- they seem to have more potent cell types and are much easier accessable etc etc. On my page on adult stemcells cell-treatment.net all aspects of the technology of adult stem cells is explained in detail- so refer to that info please, if required. Here just the picture of the cell types included in fat and some slides from Eric Duckers- Erasmus on the theme.
The ideal cell and more
So what these slides are basically saying- ideal are the MSCs, which can come from different tissue types, but you can get more-, better manipulable-and faster those preferred MSCs from adipose tissue compared to all other known sources.
Here the advantage in respect of ADRCs are quantified on the left and of course one can catch up on the quantitive issue by culturing, which has its distinct risks and disadvantages as stated on the right slide.
Personally I consider the "size" issue as extremely relevant since the cells, the bigger they get, the more prone they are to get squeezed (cell lysis) in a needle by the sheer force of injection. Thereto "the smaller the better", which applies to all cells that have to pass a human membrane like the blood-brain barrier.